{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:01:26Z","timestamp":1792011686609,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00417-024-06688-3","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:07:36Z","timestamp":1732802856000},"page":"1051-1060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease"],"prefix":"10.1007","volume":"263","author":[{"given":"Thomas","family":"Kaercher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen K.","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-2076","authenticated-orcid":false,"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"23","key":"6688_CR1","doi-asserted-by":"publisher","first-page":"9271","DOI":"10.3390\/ijms21239271","volume":"21","author":"K Tsubota","year":"2020","unstructured":"Tsubota K, Pflugfelder SC, Liu Z et al (2020) Defining Dry Eye from a clinical perspective. Int J Mol Sci 21(23):9271. https:\/\/doi.org\/10.3390\/ijms21239271","journal-title":"Int J Mol Sci"},{"key":"6688_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, MaAlves M, Bunya VY et al (2017) TFOS DEWS II Epidemiology Report. Ocul Surf 15:334\u2013365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003","journal-title":"Ocul Surf"},{"issue":"3","key":"6688_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","volume":"143","author":"B Miljanovic","year":"2007","unstructured":"Miljanovic B, Dana R, Sullivan DA, Schaumberg DA (2007) Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 143(3):409\u2013415. https:\/\/doi.org\/10.1016\/j.ajo.2006.11.060","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"6688_CR4","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1167\/iovs.16-19419","volume":"57","author":"KK Nichols","year":"2016","unstructured":"Nichols KK, Bacharach J, Holland E et al (2016) Impact of Dry Eye Disease on Work Productivity, and patients\u2019 satisfaction with Over-the-counter Dry Eye treatments. Investig Ophthalmol Vis Sci 57(7):2975\u20132982. https:\/\/doi.org\/10.1167\/iovs.16-19419","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"6688_CR5","doi-asserted-by":"publisher","unstructured":"Yu J, Asche C, Fairchild C (2011) The Economic Burden of Dry Eye Disease in the United States: A Decision Tree Analysis. Cornea. 30 (4): 379\u2013387. https:\/\/doi.org\/10.1097\/ICO.0b013e3181f7f363","DOI":"10.1097\/ICO.0b013e3181f7f363"},{"issue":"11S","key":"6688_CR6","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","volume":"124","author":"SC Pflugfelder","year":"2017","unstructured":"Pflugfelder SC, de Pavia CS (2017) The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology 124(11S):S4\u2013S13.\u00a0https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.010","journal-title":"Ophthalmology"},{"issue":"3","key":"6688_CR7","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1177\/11206721221141481","volume":"33","author":"EM Messmer","year":"2023","unstructured":"Messmer EM, Ahmad S, Benitez Del Castillo JM et al (2023) Management of inflammation in dry eye disease: recommendations from a European panel of experts. Eur J Ophthalmol 33(3):1294\u20131307. https:\/\/doi.org\/10.1177\/11206721221141481","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"6688_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09273948.2022.2027461","volume":"30","author":"KJ Hirabayashi","year":"2022","unstructured":"Hirabayashi KJ, Akpek EK, Ahmad S (2022) Outcome measures to assess dry eye severity: a review. Ocul Immunol Inflamm 30(2):282\u2013289. https:\/\/doi.org\/10.1080\/09273948.2022.2027461","journal-title":"Ocul Immunol Inflamm"},{"key":"6688_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ajo.2019.10.009","volume":"210","author":"EK Akpek","year":"2020","unstructured":"Akpek EK, Karakus S, Ramulu PY, Mathews PM (2020) Sustained gazing causes measurable decline in visual function of patients with Dry Eye. Am J Ophthalmol 210:107\u2013115. https:\/\/doi.org\/10.1016\/j.ajo.2019.10.009","journal-title":"Am J Ophthalmol"},{"key":"6688_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jtos.2021.10.007","volume":"23","author":"K Morthen","year":"2022","unstructured":"Morthen K, Magno MS, Utheim TP et al (2022) The vision-related burden of dry eye. Ocul Surf 23:207\u2013215. https:\/\/doi.org\/10.1016\/j.jtos.2021.10.007","journal-title":"Ocul Surf"},{"key":"6688_CR11","doi-asserted-by":"publisher","unstructured":"Messmer EM, Benitez-del-Castillo J, Baudouin C (2023) Treatment of dry eye disease in Europe. Edited by Anat Galor. Dry Eye Disease, Elsevier, Chap. 13 pp. 203\u2013211. https:\/\/doi.org\/10.1016\/B978-0-323-82753-9.00010-2","DOI":"10.1016\/B978-0-323-82753-9.00010-2"},{"issue":"3","key":"6688_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Nichols KK et al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15(3):276\u2013283. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008","journal-title":"Ocul Surf"},{"key":"6688_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/OPTH.S184412","volume":"13","author":"RC de Oliveira","year":"2019","unstructured":"de Oliveira RC, Wilson SE (2019) Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol 13:1115\u20131122. https:\/\/doi.org\/10.2147\/OPTH.S184412","journal-title":"Clin Ophthalmol"},{"key":"6688_CR14","doi-asserted-by":"publisher","unstructured":"Messmer EM, Ahmad S, Del Benitez JM et al (2023) Management of inflammation in dry eye disease: Recommendations from a European panel of experts. Eur J Ophthalmol 33(3):1294\u20131307. https:\/\/doi.org\/10.1177\/11206721221141481. a panel of European dry eye disease experts","DOI":"10.1177\/11206721221141481"},{"issue":"3","key":"6688_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0939-6411(03)00138-3","volume":"56","author":"F Lallemand","year":"2003","unstructured":"Lallemand F, Felt-Baeyens O, Besseghir K et al (2003) Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 56(3):307\u2013318. https:\/\/doi.org\/10.1016\/s0939-6411(03)00138-3","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"6688_CR16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40123-022-00516-9","volume":"11","author":"B Shen Lee","year":"2022","unstructured":"Shen Lee B, Toyos M, Karpecki P et al (2022) Selective pharmacologic therapies for dry eye disease treatment: efficacy, tolerability, and safety data review from preclinical studies and pivotal trials. Ophthalmol Ther 11(4):1333\u20131369. https:\/\/doi.org\/10.1007\/s40123-022-00516-9","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"6688_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/s0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL (2000) Two multicenter, randomized studies of the efficacy and safety of Ciclosporin ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107(4):631\u2013639. https:\/\/doi.org\/10.1016\/s0161-6420(99)00176-1","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"6688_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","volume":"538","author":"P Agarwal","year":"2018","unstructured":"Agarwal P, Scherer D, G\u00fcnther B, Rupenthal ID (2018) Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm 538(1\u20132):119\u2013129. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.01.019","journal-title":"Int J Pharm"},{"issue":"10","key":"6688_CR19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","volume":"40","author":"JD Sheppard","year":"2021","unstructured":"Sheppard JD, Wirta DL, McLaurin E et al (2021) A water-free 0.1% ciclosporin A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE Study. Cornea 40(10):1290\u20131297. https:\/\/doi.org\/10.1097\/ICO.0000000000002633","journal-title":"Cornea"},{"issue":"5","key":"6688_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","volume":"141","author":"E Akpek","year":"2023","unstructured":"Akpek E, Wirta D, Downing J et al (2023) Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe Dry Eye Disease: the ESSENCE-2 Randomized Clinical Trial. JAMA Ophthalmol 141(5):459\u2013466. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.0709","journal-title":"JAMA Ophthalmol"},{"key":"6688_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/OPTH.S75297","volume":"9","author":"G Ousler 3rd","year":"2015","unstructured":"Ousler G 3rd, Devries DK, Karpecki PM, Ciolino JB (2015) An evaluation of Retaine\u2122 ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye. Clin Ophthalmol 9:235\u2013243. https:\/\/doi.org\/10.2147\/OPTH.S75297","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"6688_CR22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jamaophthalmol.2021.3943","volume":"139","author":"EJ Holland","year":"2021","unstructured":"Holland EJ, Jackson MA, Donnenfeld E et al (2021) Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in patients with moderate to severe Dry Eye Disease: a Post Hoc Analysis of 2 randomized clinical trials. JAMA Ophthalmol 139(11):1200\u20131208. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.3943","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"6688_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","volume":"130","author":"J Tauber","year":"2023","unstructured":"Tauber J, Berdy GJ, Wirta DL, GOBI Study Group et al (2023) NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: results of the Randomized phase 3 GOBI Study. Ophthalmology 130(5):516\u2013524. https:\/\/doi.org\/10.1016\/j.ophtha.2022.12.021","journal-title":"Ophthalmology"},{"issue":"6","key":"6688_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/j.jcrs.0000000000001423","volume":"50","author":"EK Akpek","year":"2024","unstructured":"Akpek EK, Sheppard JD, Hamm A et al (2024) Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract. J Cataract Refract Surg 50(6):644\u2013650. https:\/\/doi.org\/10.1097\/j.jcrs.0000000000001423","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"6688_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjophthalmol-2015-308237","volume":"101","author":"PM Mathews","year":"2017","unstructured":"Mathews PM, Ramulu PY, Swenor BS et al (2017) Functional impairment of reading in patients with dry eye. Br J Ophthalmol 101(4):481\u2013486. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-308237","journal-title":"Br J Ophthalmol"},{"key":"6688_CR26","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","volume":"126","author":"DF Goldberg","year":"2019","unstructured":"Goldberg DF, Malhotra RP, Schechter BA et al (2019) A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology 126:1230\u20131237. https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.050","journal-title":"Ophthalmology"},{"issue":"4","key":"6688_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, VanSetten G, Amrane M et al (2016) Efficacy and safety of 0.1% ciclosporin a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 26(4):287\u2013296. https:\/\/doi.org\/10.5301\/ejo.5000779","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"6688_CR28","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1167\/iovs.13-11681","volume":"54","author":"J Gao","year":"2013","unstructured":"Gao J, Sana R, Calder V et al (2013) Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: Effect of Cyclosporin A. Invest Ophthalmol Vis Sci 54(7):4717\u20134733. https:\/\/doi.org\/10.1167\/iovs.13-11681","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6688_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/OPTH.S228070","volume":"14","author":"GW Jerkins","year":"2020","unstructured":"Jerkins GW, Pattar GR, Kannarr SR (2020) A review of topical cyclosporine a Formulations-A Disease-Modifying Agent for Keratoconjunctivitis Sicca. Clin Ophthalmol 14:481\u2013489. https:\/\/doi.org\/10.2147\/OPTH.S228070","journal-title":"Clin Ophthalmol"},{"key":"6688_CR30","doi-asserted-by":"publisher","unstructured":"Stern ME, Schaumburg CS, Dana R et al (2010) Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol. 3(5):425\u2013442, 2010. https:\/\/doi.org\/10.1038\/mi.2010.26","DOI":"10.1038\/mi.2010.26"},{"key":"6688_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejpb.2023.05.005","volume":"188","author":"P Agarwal","year":"2023","unstructured":"Agarwal P, Korward J, Kr\u00f6sser S, Rupenthal ID (2023) Preclinical characterization of water-free cyclosporine eye drops - factors impacting ocular penetration ex vivo and in vivo. Eur J Pharm Biopharm 188:100\u2013107. https:\/\/doi.org\/10.1016\/j.ejpb.2023.05.005","journal-title":"Eur J Pharm Biopharm"},{"key":"6688_CR32","unstructured":"Restasis USPI 2017.(AbbVie)\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050790s027lbl.pdf. Accessed 2024-11-12"},{"key":"6688_CR33","unstructured":"Cequa USPI 2018. (Sun Ophthalmics)\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210913s000lbl.pdf. Accessed 2024-11-12"},{"key":"6688_CR34","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/OPTH.S226168","volume":"13","author":"DE White","year":"2019","unstructured":"White DE, Zhao Y, Ogundele A et al (2019) Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol 13:2285\u20132292. https:\/\/doi.org\/10.2147\/OPTH.S226168","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"6688_CR35","doi-asserted-by":"publisher","first-page":"811e6","DOI":"10.1016\/S0161-6420(99)90171-9","volume":"106","author":"P Marsh","year":"1999","unstructured":"Marsh P, Pflugfelder SC (1999) Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106(4):811e6. https:\/\/doi.org\/10.1016\/S0161-6420(99)90171-9","journal-title":"Ophthalmology"},{"issue":"1","key":"6688_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/bjophthalmol-2017-311801","volume":"103","author":"A Leonardi","year":"2019","unstructured":"Leonardi A, Messmer EM, Labetoulle M et al (2019) Efficacy and safety of 0.1% ciclosporin a cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol 103(1):125\u2013131. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311801","journal-title":"Br J Ophthalmol"},{"key":"6688_CR37","doi-asserted-by":"publisher","unstructured":"Wirta DL, Galor A, Aune CA et al (2024) Long-term safety and efficacy of a water-free cyclosporine 0.1% Ophthalmic Solution for treatment of Dry Eye Disease: ESSENCE-2 OLE. Cornea. Advance online publication.\u00a0https:\/\/doi.org\/10.1097\/ICO.0000000000003567","DOI":"10.1097\/ICO.0000000000003567"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06688-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06688-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T03:02:25Z","timestamp":1747796545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06688-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6688"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06688-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were in accordance with the ethical standards and principles of the Declaration of Helsinki and its later amendments and approved by a properly constituted IRB (Alpha IRB, San Clemente, CA) per the International Conference on Harmonization (ICH) and applicable local regulatory requirements and laws.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval -\u00a0Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"T Kaercher is a member of the supervisory board of Novaliq and did not receive funding to assist with the preparation of this manuscript, JD Sheppard and EK Akpek are consultants to Novaliq. A Hamm is employee of SDC, the company that did the statistical analysis in these studies, as consultant for Novaliq. S. Kr\u00f6sser is an employee of Novaliq.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}